Vascular Disease Clinical Trials in Baltimore, Maryland
15 recruitingBaltimore, Maryland
Showing 1–15 of 15 trials
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 3
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular Disease
Amgen11,000 enrolled247 locationsNCT07136012
Recruiting
Phase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Cardiovascular DiseasesDementiaCognitive Impairment, Mild
Duke University20,000 enrolled103 locationsNCT04262206
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1333 locationsNCT07000357
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled772 locationsNCT07037433
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
Aneurysm ThoracicVascular DiseaseDissection+5 more
W.L.Gore & Associates1,500 enrolled34 locationsNCT06658730
Recruiting
Not Applicable
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Heart FailureCardiovascular DiseasesHeart Diseases+3 more
Cardiac Dimensions, Inc.300 enrolled92 locationsNCT03142152
Recruiting
Not Applicable
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Heart FailureCardiovascular DiseasesHeart Diseases
BrioHealth Solutions, Inc.780 enrolled37 locationsNCT06310031
Recruiting
Not Applicable
Community Health Worker-Led Intervention to Increase Cardiac Rehabilitation Participation
CVD - Cardiovascular Disease
Johns Hopkins University50 enrolled3 locationsNCT06908590
Recruiting
Phase 2
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
Heart DiseaseInflammationCoronary Arterial Disease (CAD)+3 more
Abcentra240 enrolled41 locationsNCT06927739
Recruiting
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Pulmonary Arterial HypertensionPulmonary Vascular Disease
New York Medical College2,500 enrolled14 locationsNCT02249923